Exclusive Summary

• • Simultaneous blockade of ActRIIA and ActRIIB with BIC potential, higher binding affinity to receptor A vs. Bimagrumab.
• • Significantly superior in vivo efficacy in mice and obese monkey compared with Bimagrumab.
• • Demonstrated significant better PK profile in cynomolgus monkeys versus Bimagrumab, Q4W/Q8W SC administration may achieved based on human predication.
• • A pilot toxicology study results indicated a better safety profile vs. Bimagrumab.

Asset Materials

Contact Us for Full Materials